-transparent.png){kind=logo}
The AKR lymphoma-leukemia is a T lymphocyte neoplasm, most suitable as a model for human T cell malignancies. We have been interested in the process of tumor progression in the AKR lymphoma system. In the present study, two newly isolated variants, the TAU-42 and TAU-44, were characterized with respect to their biological behavior, by comparing them to a previously studied low-malignancy variant, the TAU-39. While the TAU-44 variant formed large s.c. local tumors, the TAU-42 variant formed only small growths or none at all. The TAU-42 lymphoma was found to have the highest malignant potential: it displayed very marked dissemination to spleen, lymph nodes, liver and lungs. The TAU-44 variant had an intermediate degree of metastatic potential but presented a predilection for spread to lymph nodes and spleen and was sometimes found to metastasize to peculiar organs, such as heart and pancreas. Cells derived from the different lymphoma variants varied in their immunophenotype: the highly malignant variant cells expressed more CD4 antigen than the low-malignancy one. The opposite was observed with regard to CD8. The variant cells also differed in their migrating capacity, the more malignant one exhibiting a higher motile activity. Studies on the tumor progression model of AKR lymphoma might contribute to the elucidation of the features determining the aggressiveness of T lymphocytic malignancies.
O Klein, and
A Staroselsky, and
M Huszar, and
J Hiss, and
S Kay, and
N Donin, and
L Zeidel, and
M Michowitz, and
J Leibovici
January 2000,
Cancer investigation,
O Klein, and
A Staroselsky, and
M Huszar, and
J Hiss, and
S Kay, and
N Donin, and
L Zeidel, and
M Michowitz, and
J Leibovici
June 1990,
Cancer letters,
O Klein, and
A Staroselsky, and
M Huszar, and
J Hiss, and
S Kay, and
N Donin, and
L Zeidel, and
M Michowitz, and
J Leibovici
January 1990,
Clinical & experimental metastasis,
O Klein, and
A Staroselsky, and
M Huszar, and
J Hiss, and
S Kay, and
N Donin, and
L Zeidel, and
M Michowitz, and
J Leibovici
January 1995,
Cancer biotherapy,
O Klein, and
A Staroselsky, and
M Huszar, and
J Hiss, and
S Kay, and
N Donin, and
L Zeidel, and
M Michowitz, and
J Leibovici
January 2001,
Cancer investigation,
O Klein, and
A Staroselsky, and
M Huszar, and
J Hiss, and
S Kay, and
N Donin, and
L Zeidel, and
M Michowitz, and
J Leibovici
March 1985,
Experientia,
O Klein, and
A Staroselsky, and
M Huszar, and
J Hiss, and
S Kay, and
N Donin, and
L Zeidel, and
M Michowitz, and
J Leibovici
June 1992,
International journal of experimental pathology,
O Klein, and
A Staroselsky, and
M Huszar, and
J Hiss, and
S Kay, and
N Donin, and
L Zeidel, and
M Michowitz, and
J Leibovici
May 1979,
Cell,
O Klein, and
A Staroselsky, and
M Huszar, and
J Hiss, and
S Kay, and
N Donin, and
L Zeidel, and
M Michowitz, and
J Leibovici
June 1968,
British journal of cancer,
O Klein, and
A Staroselsky, and
M Huszar, and
J Hiss, and
S Kay, and
N Donin, and
L Zeidel, and
M Michowitz, and
J Leibovici
January 1986,
Anticancer research,
